LncRNAs as an Architects in Cancer Biomarkers with Interface of Epitranscriptomics- Incipient Targets in Cancer Therapy.

LncRNAs as an Architects in Cancer Biomarkers with Interface of Epitranscriptomics- Incipient Targets in Cancer Therapy.
Curr Cancer Drug Targets. 2021 Jan 06;:
Authors: Ray SK, Mukherjee S
Abstract
Long non-coding RNAs (LncRNAs) epitomize a class of non-coding regulatory RNAs with more than 200 nucleotides long and situated in the nucleus or cytoplasm and rarely encode proteins. Accruing evidence signposts that lncRNAs act as molecular switches in different cellular activities like differentiation, apoptosis as well as reprogramming of cellular states by modifying gene expression patterns. The revelation of immense numbers of lncRNA with their widespread variety of expression patterns in different kinds of malignancy, tumor explicitness and their steadiness in circulating body fluids deliver an innovative groundwork for emerging diagnosis and treatments for cancer. Mechanisms associating lncRNAs in carcinogenesis are conquered by deregulation of cellular signaling pathways and altered epitranscriptome along with their expression. Specified these attributes, it becomes clear that the improvement of new tools to identify lncRNAs with higher affectability will be fundamental to allow the identification of expression pattern of lncRNAs in various kinds of malignant growth and may likewise be utilized to envisage cancer prognosis in addition to patients outcome. Improvement of RNA targeting based therapeutics delivering incredible prospe...

Source: Current Cancer Drug Targets - January 6, 2021 Category: Cancer & Oncology Authors: Ray SK, Mukherjee S Tags: Curr Cancer Drug Targets Source Type: research